Clarus Therapeutics Holdings, Inc. (CRXTQ)の価格はいくらですか

Clarus Therapeutics Holdings, Inc. (CRXTQ)の価格は$0.0014です

Clarus Therapeutics Holdings, Inc. (CRXTQ)の時価総額は何ですか

Clarus Therapeutics Holdings, Inc. (CRXTQ)の時価総額は$72.83Kです

Clarus Therapeutics Holdings, Inc.（CRXTQ）配当金

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

年	配当（株式分割調整済み）	変化
提供された日付のデータは十分ではありません。

年

配当（株式分割調整済み）

変化

提供された日付のデータは十分ではありません。

年	配当	変化
提供された日付のデータは十分ではありません。

年

配当

変化

提供された日付のデータは十分ではありません。

企業	配当支払い回数	国
Eli Lilly and Company LLY.US	215.00%	US
Johnson & Johnson JNJ.US	225.00%	US
AbbVie Inc. ABBV.US	53.00%	US
Roche Holding AG RO.SW	33.00%	CH
Merck & Co., Inc. MRK.US	223.00%	US

企業

配当支払い回数

国